scholarly journals TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy

2021 ◽  
Vol Volume 16 ◽  
pp. 5909-5921
Author(s):  
Shuwen Cao ◽  
Chunhao Lin ◽  
Xiuling Li ◽  
Yixia Liang ◽  
Phei Er Saw
Theranostics ◽  
2016 ◽  
Vol 6 (2) ◽  
pp. 192-203 ◽  
Author(s):  
Jinju Lee ◽  
Phei Er Saw ◽  
Vipul Gujrati ◽  
Yonghyun Lee ◽  
Hyungjun Kim ◽  
...  

2020 ◽  
Vol 8 (2) ◽  
pp. 79-90
Author(s):  
Arjun Sharma ◽  
Pravir Kumar ◽  
Rashmi K. Ambasta

Background: Silencing of several genes is critical for cancer therapy. These genes may be apoptotic gene, cell proliferation gene, DNA synthesis gene, etc. The two subunits of Ribonucleotide Reductase (RR), RRM1 and RRM2, are critical for DNA synthesis. Hence, targeting the blockage of DNA synthesis at tumor site can be a smart mode of cancer therapy. Specific targeting of blockage of RRM2 is done effectively by SiRNA. The drawbacks of siRNA delivery in the body include the poor uptake by all kinds of cells, questionable stability under physiological condition, non-target effect and ability to trigger the immune response. These obstacles may be overcome by target delivery of siRNA at the tumor site. This review presents a holistic overview regarding the role of RRM2 in controlling cancer progression. The nanoparticles are more effective due to specific characteristics like cell membrane penetration capacity, less toxicity, etc. RRM2 have been found to be elevated in different types of cancer and identified as the prognostic and predictive marker of the disease. Reductase RRM1 and RRM2 regulate the protein and gene expression of E2F, which is critical for protein expression and progression of cell cycle and cancer. The knockdown of RRM2 leads to apoptosis via Bcl2 in cancer. Both Bcl2 and E2F are critical in the progression of cancer, hence a gene that can affect both in regulating DNA replication is essential for cancer therapy. Aim: The aim of the review is to identify the related gene whose silencing may inhibit cancer progression. Conclusion: In this review, we illuminate the critical link between RRM-E2F, RRM-Bcl2, RRM-HDAC for the therapy of cancer. Altogether, this review presents an overview of all types of SiRNA targeted for cancer therapy with special emphasis on RRM2 for controlling the tumor progression.


BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zheng Wang ◽  
Jiangyong Miao ◽  
Lina Wang ◽  
Ying Liu ◽  
Hui Ji ◽  
...  

Abstract Background Presentation with massive systemic embolization as the initial manifestation of occult malignancy is infrequent. The standard management of cancer-related arterial thromboembolism has not yet been established. Case presentation We described a case of Trousseau’s syndrome resulting in acute ischemic stroke concomitant with multiple embolizations in the spleen and kidney during oral administration of dabigatran for pulmonary embolism preceding the diagnosis of a malignant tumor. A cancer-related hypercoagulable state was suspected because the patient was admitted to the neurology department due to acute ischemic stroke with three territory infarcts on diffusion-weighted imaging (DWI) in the absence of identifiable conventional risk factors and brain vessel narrowing. The patient was subsequently diagnosed with epidermal growth factor receptor (EGFR) mutation–positive non-small-cell lung cancer (NSCLC) (stage IV) with pleural metastasis. Administration of low-molecular-weight heparin followed by long-term dabigatran under effective cancer therapy comprising gefitinib and subsequent chemotherapy did not cause stroke relapse during the 1-year follow-up. Conclusions This case suggests that cancer-related hypercoagulability should be considered an important etiology for stroke patients who develop unexplained disseminated acute cerebral infarction without conventional stroke risk factors, especially concomitant with multiple organ embolization. Novel oral anticoagulants may be an alternative therapy for the long-term management of cancer-related arterial thromboembolism under effective cancer therapy.


2015 ◽  
Vol 128 (3) ◽  
pp. 1062-1067 ◽  
Author(s):  
Tianjiao Ji ◽  
Ying Zhao ◽  
Yanping Ding ◽  
Jing Wang ◽  
Ruifang Zhao ◽  
...  

2018 ◽  
Vol 7 (7) ◽  
pp. 1701510 ◽  
Author(s):  
Chenyang Xing ◽  
Shiyou Chen ◽  
Meng Qiu ◽  
Xin Liang ◽  
Quan Liu ◽  
...  

ChemPlusChem ◽  
2018 ◽  
Vol 83 (12) ◽  
pp. 1127-1134 ◽  
Author(s):  
Yixin Chen ◽  
Siyuan Xiang ◽  
Lu Wang ◽  
Mingyue Wang ◽  
Congcong Wang ◽  
...  

ACS Nano ◽  
2014 ◽  
Vol 8 (7) ◽  
pp. 6922-6933 ◽  
Author(s):  
Wenyan Yin ◽  
Liang Yan ◽  
Jie Yu ◽  
Gan Tian ◽  
Liangjun Zhou ◽  
...  

ChemPlusChem ◽  
2021 ◽  
Author(s):  
Yixin Chen ◽  
Siyuan Xiang ◽  
Lu Wang ◽  
Mingyue Wang ◽  
Congcong Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document